These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 27664866)

  • 1. Nivolumab-Induced Colitis Treated by Infliximab.
    Yanai S; Nakamura S; Matsumoto T
    Clin Gastroenterol Hepatol; 2017 Apr; 15(4):e80-e81. PubMed ID: 27664866
    [No Abstract]   [Full Text] [Related]  

  • 2. Nivolumab-Associated Colitis Mimicking Ulcerative Colitis.
    Kubo K; Kato M; Mabe K
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):A35-A36. PubMed ID: 28351793
    [No Abstract]   [Full Text] [Related]  

  • 3. Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC.
    Callens R; Tamsin A; van Zandweghe L
    J Thorac Oncol; 2019 Mar; 14(3):e49-e50. PubMed ID: 30782382
    [No Abstract]   [Full Text] [Related]  

  • 4. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
    Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
    J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
    [No Abstract]   [Full Text] [Related]  

  • 5. [Histoseminar on inflammatory bowel diseases (IBD): Case n
    Fléjou JF
    Ann Pathol; 2017 Aug; 37(4):298-301. PubMed ID: 28734677
    [No Abstract]   [Full Text] [Related]  

  • 6. Nivolumab-induced colitis in a patient with malignant melanoma: A case report and immunological analysis.
    Miyashita A; Fukushima S; Tsukamoto H; Itai H; Miyamoto H; Nakahara S; Kubo Y; Kimura T; Kuriyama H; Ihn H
    J Dermatol; 2019 Sep; 46(9):e339-e341. PubMed ID: 30908699
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.
    Zhang HC; Luo W; Wang Y
    J Immunother Cancer; 2019 Feb; 7(1):47. PubMed ID: 30777137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint Inhibitors May Cause Pseudoprogression and Dose-Limiting Side Effects.
    Wiley K
    ONS Connect; 2016 Jul; 31(7):24. PubMed ID: 30549937
    [No Abstract]   [Full Text] [Related]  

  • 9. Nivolumab plus ipilimumab in metastatic colorectal cancer.
    Gourd E
    Lancet Oncol; 2018 Mar; 19(3):e139. PubMed ID: 29395861
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple Cranial Neuropathies From Nivolumab in a Patient With Metastatic Hepatocellular Carcinoma.
    Siegel CH; Finn RS; Ho MG
    Mayo Clin Proc; 2018 Apr; 93(4):540-541. PubMed ID: 29622100
    [No Abstract]   [Full Text] [Related]  

  • 11. Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy.
    Apostolova P; Unger S; von Bubnoff D; Meiss F; Becher B; Zeiser R
    N Engl J Med; 2020 Jan; 382(3):294-296. PubMed ID: 31940706
    [No Abstract]   [Full Text] [Related]  

  • 12. Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient.
    Teramoto Y; Nakamura Y; Asami Y; Imamura T; Takahira S; Nemoto M; Sakai G; Shimada A; Noda M; Yamamoto A
    J Dermatol; 2017 May; 44(5):605-606. PubMed ID: 27334247
    [No Abstract]   [Full Text] [Related]  

  • 13. Immune-Mediated Colitis due to Concurrent Ipilimumab and Nivolumab Therapy Treated With Infliximab.
    Karanfilian B; Dalal I; Bhurwal A; Patel AV
    Am J Ther; 2020; 27(4):e415-e417. PubMed ID: 32355083
    [No Abstract]   [Full Text] [Related]  

  • 14. Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate.
    Eze C; Manapov F; Gratzke C; Schmidt-Hegemann NS; Jung A; Kirchner T; Heinemann V; Stief CG; Belka C; Boeck S
    Eur J Cancer; 2018 May; 95():109-111. PubMed ID: 29477368
    [No Abstract]   [Full Text] [Related]  

  • 15. Dramatic effect of nivolumab against melanoma and immune-related liver toxicity: A detailed histopathological and immunohistochemical analysis of nivolumab-induced liver toxicity.
    Namiki T; Nojima K; Chikazawa S; Iwamoto Y; Otsuki Y; Albusani H; Miura K; Kiyokawa Y; Asakage T; Yokozeki H
    J Dermatol; 2019 May; 46(5):e182-e183. PubMed ID: 30474878
    [No Abstract]   [Full Text] [Related]  

  • 16. Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab.
    Fujimura T; Lyu C; Tsukada A; Sato Y; Kambayashi Y; Aiba S
    J Dermatol; 2019 May; 46(5):e177-e178. PubMed ID: 30353913
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine.
    Kikuchi H; Sakuraba H; Akemoto Y; Murai Y; Fukutoku Y; Asari T; Tatsuta T; Hasui K; Hiraga H; Sawaya M; Chinda D; Mikami T; Tanaka M; Fukuda S
    Immunol Med; 2019 Mar; 42(1):39-44. PubMed ID: 30917094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature.
    Vitale MG; Baldessari C; Milella M; Buti S; Militello AM; Di Girolamo S; Fornarini G; Perri G; Basso U; Maruzzo M; Porta C; Cosmai L; Pipitone S; Cerma K; Cascinu S; Sabbatini R
    Clin Genitourin Cancer; 2019 Oct; 17(5):e903-e908. PubMed ID: 31375351
    [No Abstract]   [Full Text] [Related]  

  • 19. Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab.
    Martinot M; Ahle G; Petrosyan I; Martinez C; Gorun DM; Mohseni-Zadeh M; Fafi-Kremer S; Tebacher-Alt M
    Emerg Infect Dis; 2018 Aug; 24(8):1594-1596. PubMed ID: 30016251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case of acute-onset type 1 diabetes induced by long-term immunotherapy with nivolumab in a patient with mucosal melanoma.
    Maekawa T; Okada K; Okada H; Kado S; Kamiya K; Komine M; Murata S; Oka K; Ishibashi S; Ohtsuki M
    J Dermatol; 2019 Dec; 46(12):e463-e464. PubMed ID: 31436330
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.